Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib
N/A
15 Years
N/A
15 Years
N/A
Not Enrolling
Both
Gastrointestinal Stromal Tumors
Both
Gastrointestinal Stromal Tumors
Trial Information
Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib
Inclusion Criteria:
- Patients with metastatic or unresectable gastrointestinal stromal tumor
- Patients receiving nilotinib after failure to imatinib and sunitinib
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Yoon-Koo Kang, M.D., PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Asan Medical Center
Authority:
Korea: Food and Drug Administration
Study ID:
AMC0902
NCT ID:
NCT00976612
Start Date:
January 2009
Completion Date:
December 2011
Related Keywords:
- Gastrointestinal Stromal Tumors
- Gastrointestinal stromal tumor
- pharmacokinetics
- nilotinib
- Gastrointestinal Stromal Tumors
Name | Location |
|---|
